# China NMPA Drug Inspection - Jiangxi Zhangshu Chengfang Traditional Chinese Medicine Pieces Co., Ltd. - Xianmao

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jiangxi-zhangshu-chengfang-traditional-chinese-medicine-pieces-co-ltd/ebe2e7fb-7f70-4431-95b9-ad70a2720044/
Source feed: China

> China NMPA drug inspection for Jiangxi Zhangshu Chengfang Traditional Chinese Medicine Pieces Co., Ltd. published July 31, 2020. Drug: Xianmao. The Guizhou Provincial Drug Administration's 2020 Drug Quality Announcement (Issue 1) summarizes sampling inspections co

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Guizhou Provincial Drug Administration Drug Quality Bulletin (Drug Sampling Inspection Information Announcement) (Issue 1, 2020) (Total Issue 39)
- Company Name: Jiangxi Zhangshu Chengfang Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2020-07-31
- Drug Name: Xianmao
- Inspection Finding: Extractives and content determination
- Action Taken: Cases will be filed for investigation and prosecution, key supervision will be strengthened, and rectification will be urged.
- Summary: The Guizhou Provincial Drug Administration's 2020 Drug Quality Announcement (Issue 1) summarizes sampling inspections conducted in the second half of 2019. Governed by the Drug Administration Law of the People's Republic of China and the 2015 Chinese Pharmacopoeia, the inspections identified 24 non-compliant drug batches from 16 manufacturers, including Sichuan Yunbotang Pharmaceutical, Jiangxi Zhangshu Chengfang Traditional Chinese Medicine Slices, and Zunyi Yinhua Pharmaceutical. The identified violations involve significant quality failures, such as substandard active ingredient concentrations, excessive moisture, and high ash content. Additionally, certain products, such as pediatric cough and asthma relief granules, failed microbial limit tests, while others displayed improper physical properties or identification markers. Following these findings, regulatory departments have initiated formal investigations and prosecutions against the offending production and distribution units. The administration is enforcing key supervision over entities with recurring quality issues and has mandated immediate rectification of all identified problems to ensure public medication safety and compliance with national standards.

Company: https://www.globalkeysolutions.net/companies/jiangxi-zhangshu-chengfang-traditional-chinese-medicine-pieces-co-ltd/6459c97d-c6eb-4306-871f-6193c8c2081e/